NasdaqGS - Delayed Quote USD

Cytokinetics, Incorporated (CYTK)

31.00
+1.16
+(3.89%)
At close: May 16 at 4:00:01 PM EDT
31.55
+0.55
+(1.77%)
After hours: May 16 at 7:23:50 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
19,218
18,474
7,530
94,588
70,428
Cost of Revenue
357,679
339,408
330,123
240,813
159,938
Gross Profit
-338,461
-320,934
-322,593
-146,225
-89,510
Operating Expense
227,183
215,314
173,612
177,977
96,803
Operating Income
-565,644
-536,248
-496,205
-324,202
-186,313
Net Non Operating Interest Income Expense
-34,815
-34,978
-30,039
-39,814
-29,001
Other Income Expense
--
-18,300
--
-24,939
--
Pretax Income
-615,259
-589,526
-526,244
-388,955
-215,314
Net Income Common Stockholders
-615,259
-589,526
-526,244
-388,955
-215,314
Diluted NI Available to Com Stockholders
-615,259
-589,526
-526,244
-388,955
-215,314
Basic EPS
-5.29
-5.26
-5.45
-4.33
-2.80
Diluted EPS
-5.29
-5.26
-5.45
-4.33
-2.80
Basic Average Shares
116,122
111,979
96,524
89,825
76,886
Diluted Average Shares
116,122
111,979
96,524
89,825
76,886
Total Operating Income as Reported
-565,644
-536,248
-496,205
-324,202
-186,313
Total Expenses
584,862
554,722
503,735
418,790
256,741
Net Income from Continuing & Discontinued Operation
-615,259
-589,526
-526,244
-388,955
-215,314
Normalized Income
-616,159
-590,826
-526,244
-364,016
-215,314
Interest Income
57,322
51,534
27,629
11,342
331
Interest Expense
92,137
86,512
57,668
51,156
29,332
Net Interest Income
-34,815
-34,978
-30,039
-39,814
-29,001
EBIT
-523,122
-503,014
-468,576
-337,799
-185,982
EBITDA
-513,622
-493,483
-456,684
-331,985
-183,706
Reconciled Cost of Revenue
357,679
339,408
330,123
240,813
159,938
Reconciled Depreciation
9,500
9,531
11,892
5,814
2,276
Net Income from Continuing Operation Net Minority Interest
-615,259
-589,526
-526,244
-388,955
-215,314
Total Unusual Items Excluding Goodwill
900
1,300
0
-24,939
0
Total Unusual Items
900
1,300
0
-24,939
0
Normalized EBITDA
-514,522
-494,783
-456,684
-307,046
-183,706
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 4/30/2004

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BBIO BridgeBio Pharma, Inc.
33.84
+0.30%
 
ITOS iTeos Therapeutics, Inc.
7.81
-2.01%
 
BHVN Biohaven Ltd.
16.02
+1.26%
 
AKRO Akero Therapeutics, Inc.
38.87
-2.73%
 
RCKT Rocket Pharmaceuticals, Inc.
6.50
-3.35%
 
SRRK Scholar Rock Holding Corporation
30.55
-0.91%
 
LEGN Legend Biotech Corporation
27.78
+0.33%
 
JANX Janux Therapeutics, Inc.
24.28
+4.34%
 
CRNX Crinetics Pharmaceuticals, Inc.
31.24
+0.10%
 
XENE Xenon Pharmaceuticals Inc.
30.29
+2.43%